Participant flow

UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma · Source last updated 2016-09-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression. VAD: 3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20 High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3: Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1 Hemopoietic stem cell procurement: Collection target = 10 x 10\^6 cells/kg EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide

   id

   FG000

   title

   Study Treatment

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         231

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         231

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice